Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 12, 2026Annals of Surgery OpenOpen Access

Clinical Value of a 51-Neuroendocrine Tumor–Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAndrea FrillingACAshley CliftDSDuncan Spalding

Discussion

Loading...

Member takes

Overview

Prospective study evaluates NETest 2.0 for monitoring surgical patients with gastroenteropancreatic NETs, suggesting its clinical relevance.

Key Points

  • Evaluate the clinical utility of the NETest 2.0 gene assay for monitoring gastroenteropancreatic neuroendocrine tumors.
  • Collected blood samples at baseline and follow-up from 82 surgical patients with GEPNET.
  • Measured NETest 2.0 scores (0–100) and correlated with disease status and follow-up.
  • Significantly higher NETest 2.0 scores in deceased patients (P=0.0215 for pancreatic NET, P=0.0011 for small bowel NET).
  • Scores ≥50 associated with recurrent disease (P=0.0013); scores ≥65 linked to worse overall survival.

Cite This Study

Frilling et al. (2026) studied this question.

synapsesocial.com/papers/6a7c20ae06a85aed514b7b08https://doi.org/10.1097/as9.0000000000000700
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<scp>NETest</scp> in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms2024 · 5 citations
  2. 2Clinical Validity of NETest2.0® in Surveillance of Neuroendocrine Tumor Patients: Evidence from a NET Registry Study (NCT02270567)2026 · 2 citations
  3. 3NETest2.0® Demonstrates Superior Monitoring Performance Compared with Chromogranin A in Neuroendocrine Tumor Surveillance2026
  4. 4Clinicopathological Features and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Tumors: A Single-Center Experience2026 · 1 citations
  5. 5Analytical Validation of NETest2.0®, a Novel Multigene Blood-Based Molecular Assay for Neuroendocrine Tumors2026 · 1 citations